REVIEW
Published on 12 Aug 2025
Indoleamine 2,3-dioxygenase 1 in cancer immunotherapy: from small-molecule inhibition to PROTAC-mediated degradation
doi 10.3389/fphar.2025.1640073
- 3,022 views
- 3 citations
- Frontiers in Pharmacology
- Experimental Pharmacology and Drug Discovery
- Research Topics
- Next-Generation PROTACs in Oncology and Beyond: Exploring Therapeutic Targets and Their Degraders
Next-Generation PROTACs in Oncology and Beyond: Exploring Therapeutic Targets and Their Degraders
3,210
Total downloads
19k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 15 Apr 2025
YX-112, a novel celastrol-derived PROTAC, inhibits the development of triple-negative breast cancer by targeting the degradation of multiple proteins
doi 10.3389/fphar.2025.1571135
- 2,491 views
- 2 citations
REVIEW
Published on 26 Feb 2025
Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives
doi 10.3389/fphar.2025.1478331
- 6,837 views
REVIEW
Published on 25 Feb 2025
MLKL as an emerging machinery for modulating organelle dynamics: regulatory mechanisms, pathophysiological significance, and targeted therapeutics
doi 10.3389/fphar.2025.1512968
- 4,189 views
- 6 citations
